Our findings raise the possibility that in human atherosclerosis, increased plasma ACE2 activity in those with adverse cardiovascular outcomes reflect a persistent albeit insufficient counter-regulatory process to shift the balance away from the deleterious effects of sustained Ang II activation. The gene discussed is ACE2; the disease is atherosclerosis.